<?xml version="1.0" encoding="UTF-8" ?>








    
    
    
    













        
            
            
        <!-- FT CACHE --> 

<?xml-stylesheet title="XSL_formatting" type="text/xsl" href="http://www.ft.com/FTCOM/XSL/styleRSSFeed.xsl"?><rss xmlns:java="java" xmlns:ft="http://www.ft.com/FTRSSExtensions" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><atom:link type="application/xml" rel="self" href="http://www.ft.com/rss/companies/health"/><title>FT.com - Health</title><link>http://www.ft.com/companies/health</link><ft:rsslink>http://www.ft.com/rss/companies/health</ft:rsslink><description>FT.com - Health</description><language>en</language><copyright>© Copyright The Financial Times Ltd 2009. "FT" and "Financial Times" are trademarks of the Financial Times. See http://www.ft.com/servicestools/help/terms#legal1 for the terms and conditions of reuse.</copyright><webMaster>client.support@ft.com (Client Support)</webMaster><pubDate>Fri, 4 Dec 2009 00:01:37 +0000</pubDate><lastBuildDate>Sun, 6 Dec 2009 07:00:03 +0000</lastBuildDate><category>Newspapers</category><ttl>15</ttl><image><url>http://news.ft.com/cms/d1f3ce1a-6bbe-11da-bb53-0000779e2340.gif</url><title>FT.com - Health</title><link>http://www.ft.com/companies/health</link></image><rating>(PICS-1.1 "http://www.classify.org/safesurf/" L gen true for "http://www.ft.com/" r (SS~~000 1))</rating><item><title>Venture capitalists re-emerge for Movetis IPO</title><link>http://traxfer.ft.com/cms/s/0/cb985af0-e044-11de-8494-00144feab49a.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/cb985af0-e044-11de-8494-00144feab49a.html</guid><description>A two-year drought of initial public offerings by venture capital-backed companies in Europe will be broken when the gastrointestinal drugs group floats on Euronext in Brussels</description><pubDate>Fri, 4 Dec 2009 00:01:37 +0000</pubDate></item><item><title>Gilead set to benefit from HIV guidelines</title><link>http://traxfer.ft.com/cms/s/0/f8be7820-dea0-11de-adff-00144feab49a.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/f8be7820-dea0-11de-adff-00144feab49a.html</guid><description>US biotech company is poised to benefit from new WHO guidelines for HIV which call for earlier treatment using more up-to-date drugs</description><pubDate>Wed, 2 Dec 2009 12:45:03 +0000</pubDate></item><item><title>Drugs groups face increase in tax rates</title><link>http://traxfer.ft.com/cms/s/0/ec2cd406-dde9-11de-b8e2-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/ec2cd406-dde9-11de-b8e2-00144feabdc0.html</guid><description>PwC says rising public sector deficits and a shift in the strategy of pharmaceutical companies will intensify countries' efforts to clamp down on methods used to keep taxes low</description><pubDate>Tue, 1 Dec 2009 00:55:30 +0000</pubDate></item><item><title>Tests boosts Immunodiagnostic Systems</title><link>http://traxfer.ft.com/cms/s/0/b0be09dc-dda6-11de-9f8b-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/b0be09dc-dda6-11de-9f8b-00144feabdc0.html</guid><description>The surging popularity of vitamin D tests has lifted profits at the medical testing company as it promotes a new system that will greatly increase medical diagnosis</description><pubDate>Mon, 30 Nov 2009 19:32:26 +0000</pubDate></item><item><title>GSK to cut drug prices for developing countries</title><link>http://traxfer.ft.com/cms/s/0/9848b498-dd14-11de-ad60-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/9848b498-dd14-11de-ad60-00144feabdc0.html</guid><description>The UK drugs maker is to cut signi­ficantly the prices of its medicine in emerging economies next spring, in a move to tap demand from the faster-growing economies as western markets stagnate</description><pubDate>Sun, 29 Nov 2009 22:30:47 +0000</pubDate></item><item><title>Warning sounded over drug tenders</title><link>http://traxfer.ft.com/cms/s/0/bf5ca778-dd24-11de-ad60-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/bf5ca778-dd24-11de-ad60-00144feabdc0.html</guid><description>Large-scale government tenders for generic medicines are threatening the future of the off-patent pharmaceuticals industry, the new president of the trade body has warned</description><pubDate>Sun, 29 Nov 2009 21:50:55 +0000</pubDate></item><item><title>Turning the world of drugs upside down </title><link>http://traxfer.ft.com/cms/s/0/0670e678-dd03-11de-ad60-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/0670e678-dd03-11de-ad60-00144feabdc0.html</guid><description>When Abbas Hussain was recruited by GlaxoSmith-Kline's chief executive Andrew Witty last year to head emerging markets, the idea was to shift the pharmaceutical company away from 'white pills in western markets'</description><pubDate>Sun, 29 Nov 2009 17:42:30 +0000</pubDate></item><item><title>Glaxo hopes high for Cambridge science centre </title><link>http://traxfer.ft.com/cms/s/0/9e2e0bd2-dcf7-11de-ad60-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/9e2e0bd2-dcf7-11de-ad60-00144feabdc0.html</guid><description>GlaxoSmithKline is to spearhead the development of a £170m biotech science park in an effort to create a life sciences cluster in the east of England that can rival the leading US centres of Boston and North Carolina</description><pubDate>Sun, 29 Nov 2009 16:18:50 +0000</pubDate></item><item><title>Milestone payments boost Vectura</title><link>http://traxfer.ft.com/cms/s/0/8a0e026e-db36-11de-9023-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/8a0e026e-db36-11de-9023-00144feabdc0.html</guid><description>Revenues at the drug delivery group jump 71% to £22.8m, helped by a jump in milestone payments from pharma groups and increased royalties on its marketed products</description><pubDate>Sat, 28 Nov 2009 02:01:17 +0000</pubDate></item><item><title>Pfizer takes aim in patent row</title><link>http://traxfer.ft.com/cms/s/0/19afde18-d922-11de-b2d5-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/19afde18-d922-11de-b2d5-00144feabdc0.html</guid><description>The US pharmaceutical group alleges patent infringement against the largest drugsmaker in the Philippiness</description><pubDate>Tue, 24 Nov 2009 23:35:24 +0000</pubDate></item><item><title>Forgetful patients lift support consultancies</title><link>http://traxfer.ft.com/cms/s/0/cad63d0c-d929-11de-b2d5-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/cad63d0c-d929-11de-b2d5-00144feabdc0.html</guid><description>A growing number of companies are being sought out by pharmaceutical groups as they explore strategic ways to improve patient "adherence"</description><pubDate>Tue, 24 Nov 2009 23:03:38 +0000</pubDate></item><item><title>Sanofi chief lays out distinctive strategy</title><link>http://traxfer.ft.com/cms/s/0/d461b6ac-d790-11de-b578-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/d461b6ac-d790-11de-b578-00144feabdc0.html</guid><description>The chief executive of Sanofi-Aventis criticises the past dominance of science over commerce in the French pharmaceuticals group and the stifling of the companies it acquired, as he lays out a distinctive strategy almost one year into the job</description><pubDate>Sun, 22 Nov 2009 19:51:22 +0000</pubDate></item><item><title>J&amp;J stays true to its diversified model</title><link>http://traxfer.ft.com/cms/s/0/d6e0a888-d606-11de-b80f-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/d6e0a888-d606-11de-b80f-00144feabdc0.html</guid><description>Johnson &amp; Johnson defends its strategy, with its three broad divisions of medical devices, consumer health and pharmaceuticals, even as the approach fails to shield it from industry pains</description><pubDate>Fri, 20 Nov 2009 20:39:24 +0000</pubDate></item><item><title>Philip Morris ordered to pay $300m to smoker</title><link>http://traxfer.ft.com/cms/s/0/94d403da-d57b-11de-81ee-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/94d403da-d57b-11de-81ee-00144feabdc0.html</guid><description>A Florida jury orders cigarette maker Philip Morris USA to pay $300m in damages to a 61-year-old ex-smoker who is wheelchair-bound by emphysema</description><pubDate>Fri, 20 Nov 2009 02:33:47 +0000</pubDate></item><item><title>Regulations trim growth at United Drug</title><link>http://traxfer.ft.com/cms/s/0/84f26952-d427-11de-990c-00144feabdc0.html?o=%2Frss%2Fcompanies%2Fhealth</link><guid>http://www.ft.com/cms/s/0/84f26952-d427-11de-990c-00144feabdc0.html</guid><description>Reduced prices in its main Irish markets have crimped sales growth at the healthcare products supplier, in spite of strong growth in its contract sales and drug packaging businesses</description><pubDate>Thu, 19 Nov 2009 01:54:51 +0000</pubDate></item></channel></rss>






    


